The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have formalised a joint oncology early-dialogue cluster aimed at promoting early discussion and regulatory information sharing for oncology products during the pre-authorisation phase. The terms of reference, published by EMA on 17 July 2026, outline a framework for monthly virtual teleconferences where the two agencies will engage in product- or class-specific discussions on topics such as clinical trial design, data extrapolation, labelling, and risk management. The initiative is designed to encourage early alignment with sponsors and to share best practices addressing scientific and regulatory barriers to global oncology product development.
The cluster builds on existing collaboration between EMA and FDA, formalising a structured dialogue that had previously operated on an ad-hoc basis. Under the terms of reference, meetings will be scheduled monthly on the same week as EMA's Scientific Advice Working Group, with each session limited to a maximum of four topics. The agenda will be set jointly: EMA will draft a list of monthly topics, and FDA will supplement it with ongoing Investigational New Drug (IND) topics of interest. Urgent topics may be added by mutual agreement. The cluster is intended to complement other international platforms, such as the Oncology International Cluster involving regulators from Canada, Japan, Australia, and Singapore, to avoid duplication.
Membership includes EMA scientific committees and working party members (notably from the Committee for Medicinal Products for Human Use, Scientific Advice Working Party, and Oncology Working Party), EU national experts, and EMA staff from therapeutic offices and scientific evidence generation units. FDA participants will include the Oncology Center of Excellence International Team, Office of Oncologic Diseases leadership, and review staff relevant to the topics discussed. The cluster leads will decide which topics are appropriate for bilateral discussion and which should be deferred to other forums.
The terms of reference were agreed on 31 October 2025, as indicated in the document, and published by EMA on 17 July 2026. The document does not specify a start date for the monthly meetings, but the framework is now in place for regular exchanges. The initiative is expected to benefit pharmaceutical sponsors developing oncology products by providing more consistent regulatory feedback across the two agencies, potentially reducing duplication of clinical trials and accelerating patient access to new therapies. However, the cluster's impact will depend on the willingness of sponsors to engage early and on the agencies' ability to align on divergent regulatory standards, particularly around trial endpoints and data requirements.
Stakeholders most affected include oncology drug developers, who may face reduced regulatory uncertainty but also increased expectations for early dialogue; EMA and FDA review staff, who will need to allocate resources for monthly meetings and topic preparation; and patients, who could ultimately benefit from faster global development timelines. The cluster does not create binding commitments, and each agency retains its independent decision-making authority, meaning that differences in regulatory outcomes may persist despite the dialogue.